Literature DB >> 31837596

Inflammasomes and the fine line between defense and disease.

Shelbi Christgen1, Thirumala-Devi Kanneganti2.   

Abstract

Recognition of invading pathogens and execution of defensive responses are crucial steps in successfully combating infectious diseases. Inflammasomes are a group of diverse, signal-transducing complexes with key roles in both processes. While the responses mediated by inflammasomes are vital to host defense, aberrations in inflammasome regulation or activity can lead to the development of autoimmune and sterile inflammatory diseases, including cancer. The field of inflammasome research has rapidly expanded to identify novel regulatory pathways, new inflammasome components, and the mechanistic details of the activation of these complexes. In this review, we discuss recent insights into the regulation of inflammasomes by interferon regulatory factor proteins, newly discovered mechanisms of activation for the NLRP1b and NLRP6 inflammasomes, and recent studies exploring the viability of inflammasome-modulating immunotherapies.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31837596      PMCID: PMC7067632          DOI: 10.1016/j.coi.2019.11.007

Source DB:  PubMed          Journal:  Curr Opin Immunol        ISSN: 0952-7915            Impact factor:   7.486


  58 in total

1.  The NLRC4 inflammasome receptors for bacterial flagellin and type III secretion apparatus.

Authors:  Yue Zhao; Jieling Yang; Jianjin Shi; Yi-Nan Gong; Qiuhe Lu; Hao Xu; Liping Liu; Feng Shao
Journal:  Nature       Date:  2011-09-14       Impact factor: 49.962

2.  Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS).

Authors:  Paul M Ridker; Tom Thuren; Andrew Zalewski; Peter Libby
Journal:  Am Heart J       Date:  2011-09-14       Impact factor: 4.749

Review 3.  Diverging inflammasome signals in tumorigenesis and potential targeting.

Authors:  Rajendra Karki; Thirumala-Devi Kanneganti
Journal:  Nat Rev Cancer       Date:  2019-04       Impact factor: 60.716

4.  Autoinflammatory syndromes and cellular responses to stress: pathophysiology, diagnosis and new treatment perspectives.

Authors:  Sinisa Savic; Laura J Dickie; Miriam Wittmann; Michael F McDermott
Journal:  Best Pract Res Clin Rheumatol       Date:  2012-08       Impact factor: 4.098

5.  Pore-forming activity and structural autoinhibition of the gasdermin family.

Authors:  Jingjin Ding; Kun Wang; Wang Liu; Yang She; Qi Sun; Jianjin Shi; Hanzi Sun; Da-Cheng Wang; Feng Shao
Journal:  Nature       Date:  2016-06-08       Impact factor: 49.962

6.  Pyrin inflammasome activation and RhoA signaling in the autoinflammatory diseases FMF and HIDS.

Authors:  Yong Hwan Park; Geryl Wood; Daniel L Kastner; Jae Jin Chae
Journal:  Nat Immunol       Date:  2016-06-06       Impact factor: 25.606

7.  TAK1 restricts spontaneous NLRP3 activation and cell death to control myeloid proliferation.

Authors:  R K Subbarao Malireddi; Prajwal Gurung; Jayadev Mavuluri; Tejasvi Krishna Dasari; Jeffery M Klco; Hongbo Chi; Thirumala-Devi Kanneganti
Journal:  J Exp Med       Date:  2018-03-02       Impact factor: 14.307

8.  Targeting TMEM176B Enhances Antitumor Immunity and Augments the Efficacy of Immune Checkpoint Blockers by Unleashing Inflammasome Activation.

Authors:  Mercedes Segovia; Sofia Russo; Mathias Jeldres; Yamil D Mahmoud; Valentina Perez; Maite Duhalde; Pierre Charnet; Matthieu Rousset; Sabina Victoria; Florencia Veigas; Cédric Louvet; Bernard Vanhove; R Andrés Floto; Ignacio Anegon; Maria Cristina Cuturi; M Romina Girotti; Gabriel A Rabinovich; Marcelo Hill
Journal:  Cancer Cell       Date:  2019-05-13       Impact factor: 31.743

9.  Type I interferon signaling is required for activation of the inflammasome during Francisella infection.

Authors:  Thomas Henry; Anna Brotcke; David S Weiss; Lucinda J Thompson; Denise M Monack
Journal:  J Exp Med       Date:  2007-04-23       Impact factor: 14.307

10.  RIP1-driven autoinflammation targets IL-1α independently of inflammasomes and RIP3.

Authors:  John R Lukens; Peter Vogel; Gordon R Johnson; Michelle A Kelliher; Yoichiro Iwakura; Mohamed Lamkanfi; Thirumala-Devi Kanneganti
Journal:  Nature       Date:  2013-05-26       Impact factor: 49.962

View more
  29 in total

Review 1.  NLRP3 inflammasome in cancer and metabolic diseases.

Authors:  Bhesh Raj Sharma; Thirumala-Devi Kanneganti
Journal:  Nat Immunol       Date:  2021-03-11       Impact factor: 25.606

Review 2.  Programming inflammatory cell death for therapy.

Authors:  Shelbi Christgen; Rebecca E Tweedell; Thirumala-Devi Kanneganti
Journal:  Pharmacol Ther       Date:  2021-10-04       Impact factor: 12.310

3.  The Ala134Thr variant in TMEM176B exerts a beneficial role in colorectal cancer prognosis by increasing NLRP3 inflammasome activation.

Authors:  Raylane Adrielle Gonçalves Cambui; Fernanda Pereira Fernandes; Vinicius Nunes Cordeiro Leal; Edione Cristina Reis; Dhemerson Souza de Lima; Gilmar Ferreira do Espírito Santo; Rosa Maria Elias; Alessandra Pontillo
Journal:  J Cancer Res Clin Oncol       Date:  2022-08-18       Impact factor: 4.322

Review 4.  Role of inflammasome activation in tumor immunity triggered by immune checkpoint blockers.

Authors:  M Segovia; S Russo; M R Girotti; G A Rabinovich; M Hill
Journal:  Clin Exp Immunol       Date:  2020-05       Impact factor: 4.330

5.  Hydrogen Sulfide and the Immune System.

Authors:  Peter Rose; Yi-Zhun Zhu; Philip K Moore
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 6.  The Signaling Pathways Regulating NLRP3 Inflammasome Activation.

Authors:  Ming-Ye Chen; Xun-Jia Ye; Xian-Hui He; Dong-Yun Ouyang
Journal:  Inflammation       Date:  2021-05-19       Impact factor: 4.092

Review 7.  The Nlrp3 inflammasome - the evolving story of its positive and negative effects on hematopoiesis.

Authors:  Mariusz Z Ratajczak; Magdalena Kucia
Journal:  Curr Opin Hematol       Date:  2021-07-01       Impact factor: 3.218

Review 8.  Innate immunity: the first line of defense against SARS-CoV-2.

Authors:  Michael S Diamond; Thirumala-Devi Kanneganti
Journal:  Nat Immunol       Date:  2022-02-01       Impact factor: 31.250

Review 9.  Inflammasome and Mitophagy Connection in Health and Disease.

Authors:  Jae-Min Yuk; Prashanta Silwal; Eun-Kyeong Jo
Journal:  Int J Mol Sci       Date:  2020-07-01       Impact factor: 5.923

10.  Molecular Mechanisms of the Toll-Like Receptor, STING, MAVS, Inflammasome, and Interferon Pathways.

Authors:  Nathan P Manes; Aleksandra Nita-Lazar
Journal:  mSystems       Date:  2021-06-29       Impact factor: 6.496

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.